Aspivix revolutionizes women’s healthcare with Carevix™, a non-invasive method that replaces cervical tenaculum, making intrauterine device (IUD) procedures gentler and more accessible. By reducing pain deterring 30% of women, we’re helping millions access effective contraception, reducing unintended pregnancies with profound social and medical impacts. Join us to empower women worldwide and secure an attractive return on investment!
In the market
19.795.000€
2027
Medical devices
10.45%
800€
Share this project on your website.
Copy and paste the following code into your content.
Millions of women avoid intrauterine devices (IUDs)—a contraceptive method with more than 99% effectiveness—because of the pain caused by current placement techniques. This avoidance contributes to the roughly 121 million unintended pregnancies that occur every year, with significant personal and societal consequences.
Aspivix is addressing this barrier with Carevix™, a modern, non-invasive device designed to replace the outdated cervical tenaculum—a sharp, clamp-like tool traditionally used to stabilise the cervix during gynaecological procedures. By stabilising the cervix gently through suction, Carevix™ offers a dramatically improved experience for women while ensuring the safety and reliability healthcare providers demand.
Regulatory Excellence
Carevix™ is FDA-cleared for the U.S., CE Mark-approved under Europe’s stringent MDR regulations, and authorized in the U.K., Switzerland, and Brazil, ensuring global accessibility.
Strategic Partnership
A collaboration with Bayer Switzerland, a leader in IUDs, underscores strong industry confidence in Carevix™.
Proven Benefits
Validated Results
Demonstrated efficacy in a randomized controlled trial (RCT) and proven usability in 1,300 procedures during early adoption.
Clear Market Need
Up to 30% of women avoid IUDs due to fear of pain. Carevix™ removes this barrier, making contraception more accessible.
Sustainability
Aspivix is offsetting its carbon footprint, and is working on integrating bio-sourced materials into its products advancing sustainable healthcare.
By investing in Aspivix, you’re contributing to a future where women have better access to gentle, effective contraceptive solutions. Together, we can empower millions and make a lasting social impact while driving meaningful returns.
Join us in making a difference.
Gynaecological procedures, such as the insertion of intrauterine devices (IUDs), are often performed with the tenaculum, an obsolete instrument that pierces cervical tissue with sharp hooks. This method causes pain, bleeding and trauma in millions of women each year, with 89% of patients reporting significant discomfort during use.
Aspivix proposes an innovative alternative with Carevix, an atraumatic cervical stabiliser that uses vacuum suction instead of hooks, reducing pain and bleeding by more than 70%. With FDA approval, CE marking and a strong patent portfolio, Carevix has been validated in clinical studies and in more than 600 real cases, showing its efficacy and safety.
This investment round will allow Aspivix to expand the launch of Carevix in Europe and the US, optimise its manufacturing and advance the development of new devices. In a market that directly impacts the health and well-being of millions of women, Aspivix represents an opportunity to transform modern gynaecology.
Aspivix faces key challenges in adopting its technology and expanding its production. Convincing healthcare professionals to replace a traditional instrument such as the tenaculum with Carevix requires significant effort in education and training. In addition, ensuring scalable production is critical to meet demand in key markets such as the European Union and the United States, while ensuring optimisation in manufacturing and distribution.
Already have an account? Please login here .